Rivaroxaban Therapy Resulting in the Resolution of Right Atrial Thrombosis Resistant to Ordinary Control with Warfarin in a Patient with Atrial Fibrillation

Hiroaki Kawano; Yusuke Kohno; Seiya Izumida; Akira Tsuneto; Satoki Fukae; Masayoshi Takeno; Yuji Koide; Koji Maemura

doi:10.2169/internalmedicine.54.3003

CASE REPORTS

Rivaroxaban Therapy Resulting in the Resolution of Right Atrial Thrombosis Resistant to Ordinary Control with Warfarin in a Patient with Atrial Fibrillation

Hiroaki Kawano, Yusuke Kohno, Seiya Izumida, Akira Tsuneto, Satoki Fukae, Masayoshi Takeno, Yuji Koide, Koji Maemura

Author information

Hiroaki Kawano
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Yusuke Kohno
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Seiya Izumida
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Akira Tsuneto
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Satoki Fukae
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Masayoshi Takeno
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Yuji Koide
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Koji Maemura
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan

Keywords: atrial fibrillation, anticoagulant, cancer, thrombus, warfarin

JOURNAL OPEN ACCESS

2015 Volume 54 Issue 6 Pages 601-604

DOI https://doi.org/10.2169/internalmedicine.54.3003

Details

Abstract

A 72-year-old man with non-valvular atrial fibrillation and metastatic liver and lung cancer after surgery for colon cancer developed thrombosis in the right atrium one month after decreasing the dose of warfarin due to the introduction of double anti-platelet therapy for coronary stent implantation. Restoring the warfarin dose with ordinary control for two months did not result in any changes in the size of the thrombus; however, the subsequent substitution of rivaroxaban (oral treatment with a direct Factor Xa inhibitor) for warfarin ultimately resolved the thrombosis.

Corresponding author

Register with J-STAGE for free!